AbbVie Inc. (ABBV) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
AbbVie Inc. (ABBV) Profile & Business Summary
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Key Information
| Ticker | ABBV |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.abbvie.com |
Market Trend Overview for ABBV
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-11-17 (ET)
As of 2026-11-17, ABBV is moving sideways with low volatility. Over the longer term, the trend remains bullish.
ABBV last closed at 292.82. The price is about 1.1 ATR above its recent average price (285.92), and the market is currently in a sideways market with low volatility. Price at 292.82 is moving between minor support near 281.23 and minor resistance near 298.74. Direction remains unclear. View Support & Resistance from Options
Price is moving in a tight range. This often leads to a stronger move once the range breaks, increasing one-sided risk.
Trend score: 40 out of 100. Overall alignment is unclear. The market is currently in a sideways phase with tightening price movement. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 268.06. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-10-12, reflecting a technical shift toward positive directional alignment.
[2026-11-11] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model still sees a directional lean, but the edge is not thick enough after adjusting for reward/risk.
The model does not deploy this setup because the directional lean exists, but the edge is still not thick enough after risk adjustment, reward/risk remains too thin at 0.12 after adjustment, and recent price behavior has shown failed reversal memory. Predictability is 43%, agreement is 91%, and reversal risk is 15%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 55 trading days, with turnover-based decay. The sample period is 2026-09-01 to 2026-11-17. The current price is 292.82, 5.08% above the estimated average cost of 278.66. An estimated 87.9% of recent positioning is below the current price, while 11.6% is above it. The peak-density price is 289.00. The largest concentrated cost region is 260.10 to 266.10 and contains 20.0% of the estimated distribution. The current price is within the 291.50 to 295.50 cost region. The nearest region below the current price is 287.50 to 291.10.
Short Interest & Covering Risk for ABBV
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 45%)
Structure Analysis
ABBV Short positioning looks normal. Current days to cover is 3.3 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 37/100, DTC percentile 69%) as price consolidates near recent highs (20D return 1.3%) with short positioning continuing to expand and liquidity softening modestly (volume -7%).
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Price action is compressing (range is tightening), which can make breaks more sensitive. Price is consolidating near highs with a weak upward bias; surface strength may mask a more fragile structure. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. High-level consolidation and compression suggest a fragile upside structure. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-10-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.